Different evolutionary pathway of B*570101 and B*5801 (B17 group) alleles based in intron sequences

Two theories about MHC allele generation have been put forward: (1) point mutation diversification and/or (2) gene conversion events. A model supporting the existence of both of these mechanisms is shown in this paper; the possible evolution of the HLA-B*570101 and HLA-B*5801 alleles (which belong to the HLA-B17 serology group) is studied. The hypothesis favoured is that gene conversion events have originated these alleles, because intron sequences are also analysed. Evolution by point mutation should only be accepted if flanking introns have also been sequenced.The nucleotide sequence data (exons and introns) reported in this paper have been sequenced in our laboratory. They are in the GenBank nucleotide sequence database and have been assigned the accession numbers: B*150101—(a) exon 1, L79939; (b) exon 2 and exon 3, L48400; (c) intron 1, L76249; (d) intron 2, L42468; B*1515—(a) exon 1, exon 2 and exon 3, L49343; (b) intron 1 and intron 2, L76254; B*1539—(a) exon 2, AF033501; (b) exon 3, AF033502; (c) intron 1, AF034961; (d) intron 2 AF034962; B*350101—(a) exon 1, exon 2 and exon 3, L63544; (b) intron 1, L79921; (c) intron 2, L57505; B*510101—(a) exon 1, L77204; (b) exon 2 and exon 3, L47985; (c) intron 1, L76245; (d) intron 2, L42469; B*520102—(a) exon 1, L77205; (b) exon 2 and exon 3, L47984; (c) intron 1, L76244; (d) intron 2, L76251; B*5301—(a) exon 1, intron 1, exon 2, intron 2 and exon 3, U90566; B*1302—(a) intron 1, exon 2, intron 2, exon 3, AF196182; B*400101/02—(a) exon 2 and exon 3, L79937; (b) intron 1, L79919; (c) intron 2, L76629; B*4101—(a) intron 1, exon 2, intron 2 and exon 3, U90560; B*4102 (a) intron 1, exon 2, intron 2 and exon 3, AF 126199; B*4501—(a) intron 1, exon 2, intron 2 and exon 3, U90562; B*570101—(a) intron 1, exon 2, intron 2 and exon 3, AF196183; B*5801—(a) intron 1, exon 2, intron 2 and exon 3, AF196184All exon sequences were officially assigned as confirmatory by the WHO Nomenclature Committee in December 2003: B*1302, B*150101, B*350101, B*400101/02, B*4101, B*510101, B*570101, B*5801, B*5301, B*4501, B*520102, B*1515, B*4102 and B*1539. This follows the agreed policy that, subject to the conditions stated in the Nomenclature Report [Marsh et al. (2002) Tissue Antigens 60:407–464], names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report     

The HLA molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 share an extensive overlap in peptide binding specificity

Assays to measure the binding capacity of peptides for HLA-DQA1*0501/B*0201 (DQ2.3) and DQA1*0301/B*0302 (DQ3.2) were developed using solubilized MHC molecules purified from EBV-transformed cell lines. These quantitative assays, based on the principle of the inhibition of binding of a high-affinity radiolabeled ligand, were validated by examining the binding capacity of known DQ-restricted epitopes or ligands. The availability of these assays allowed an investigation of patterns of cross-reactivity between different DQ molecules and with various common DR molecules. DQ2.3 and DQ3.2 were found to have significantly overlapping peptide binding repertoires. Specifically, of 13 peptides that bound either DQ2.3 or DQ3.2, nine (69.2%) bound both. The molecular basis of this high degree of cross-reactivity was further investigated with panels of single substitution analogs of the thyroid peroxidase 632-645Y epitope. It was found that DQ2.3 and DQ3.2 bind the same ligands by using similar anchor residues but different registers. These data suggest that in analogy to what was previously described for HLA-DR molecules, HLA-DQ supertypes characterized by largely overlapping binding repertoires can be defined. In light of the known linkage of both HLA-DQ2.3 and -DQ3.2 with insulin-dependent diabetes mellitus and celiac disease, these results might have important implications for understanding HLA class II autoimmune disease associations.     

Cw * 1505: a novel HLA-C allele isolated from a B * 7301 haplotype

The nucleotide sequence data reported in this paper have been submitted to the EMBL database and have been assigned the accession number X78343. The name Cw ^*1505 was officially assigned by the WHO Nomenclature Committee in May 1994. This follows the agreed policy that, subject to the conditions stated in the most recent Nomenclature Report (The WHO Nomenclature Committee 1992), names will be assigned to new sequences as they are identified. Lists of such new names will be published in he following WHO Nomenclature Report     

B3LYP/6-311++G* * study of structure and spin-spin coupling constant in heparin disaccharide

Structures of heparin disaccharide have been analyzed by DFT using the B3LYP/6-311++G( * *) method. The optimized geometries of two forms of this disaccharide, differing in the conformation ((1)C(4) and (2)S(0)) of the IdoA2S residue, confirmed considerable influences of the sulfate and the carboxylate groups upon the pyranose ring geometries. The computed energies showed that disaccharide having the (1)C(4) form of the IdoA2S residue is more stable than that with the (2)S(0) form. Interatomic distances, bond and torsion angles showed that interconversion of the IdoA2S residue results in geometry changes in the GlcN,6S residue as well. Three-bond proton-proton and proton-carbon spin-spin coupling constants computed for both forms agree with the experimental data and indicate that only two chair forms contribute to the conformational equilibrium in disaccharide. Influences of the charged groups upon the magnitudes of spin-spin coupling constants are also discussed.     

Subcellular Effects of Cytochalasin B and Dimethylsulfoxide on Paramecium aurelia*

SYNOPSIS. Paramecium aurelia syngen 4, stock 57 (sensitive) cultivated in Cerophyl infusion were exposed to cytochalasin B CB and dimethylsulfoxide (DMSO), the solvent for CB, to distinguish between the effects of these agents on a cellular system. DMSO significantly inhibited survival, fission rate, [³H]leucine incorporation, and cell size. CB-treated cells generally had slower division and poorer survival rates than cells exposed to the equivalent DMSO concentration, although the [3H]leucine incorporation was generally greater at the lower CB concentrations than for DMSO alone. As seen by electron microscopy and a new grycerination technic for observing polysomes, DMSO caused nuclear (nucleolar, chromatin) abnormalities as well as membrane degradation and polysomal breakdown; CB caused the formation of aberrant membrane structures and ribosomal tetramers, crystals, and tubes.     

CYP1A1 *2B and *4 polymorphisms are associated with lung cancer susceptibility in Mexican patients

BACKGROUND: CYP1A1 is a gene involved in the high aryl hydrocarbon hydroxylase -inducible phenotype, which is a genetically-determined variation among individuals that has been associated with lung cancer risk. More specifically, CYP1A1 *2B and *4 polymorphisms have been associated with high susceptibility to lung cancer among cigarette smokers. MATERIALS AND METHODS: DNA was obtained from blood samples and we studied by PCR-RFLP the distribution of CYP1A1 *2B (n=248) and *4 (n=222) polymorphisms in healthy controls and 222 lung cancer patients from a Mexican population. RESULTS: Comparisons between groups showed an increased risk for lung cancer patients of *2B/*2B (18%; OR 7.6; 95% CI 3.0-19.2) and *4/ *4 genotypes (15%; OR 11.45; 95% CI 2.19-59.85) compared to the control group (1% for *2B/ *2B and 4.4% for *4/ *4). A significant association between lung cancer and homozygous *2B/ *2B passive smokers and *4/*4 ever (cigarettes) and passive smokers was also observed (p<0.05). Multivariate analysis revealed an increased risk for the *2B/*2B genotype (OR 6.83), as well as for *4/*4 (OR 28.8). CONCLUSION: The results of the study indicate a significant association between *2B/*2B and *4/*4 genotypes and the risk of developing lung cancer among Mexicans.     

High T cell epitope sharing between two HLA-B27 subtypes (B*2705 and B*2709) differentially associated to ankylosing spondylitis.

HLA-B*2705 is strongly associated with ankylosing spondylitis (AS) and reactive arthritis. In contrast, B*2709 has been reported to be more weakly or not associated to AS. These two molecules differ by a single amino acid change: aspartic acid in B*2705 or histidine in B*2709 at position 116. In this study, we analyzed the degree of T cell epitope sharing between the two subtypes. Ten allospecific T cell clones raised against B*2705, 10 clones raised against B*2703 but cross-reactive with B*2705, and 10 clones raised against B*2709 were examined for their capacity to lyse B*2705 and B*2709 target cells. The anti-B*2705 and anti-B*2703 CTL were peptide dependent as demonstrated by their failure to lyse TAP-deficient B*2705-T2 transfectant cells. Eight of the anti-B*2705 and five of the anti-B*2703 CTL clones lysed B*2709 targets. The degree of cross-reaction between B*2705 and B*2709 was donor dependent. In addition, the effect of the B*2709 mutation (D116H) on allorecognition was smaller than the effect of the other naturally occurring subtype change at this position, D116Y. These results demonstrate that B*2705 and B*2709 are the antigenically closest HLA-B27 subtypes. Because allospecific T cell recognition is peptide dependent, our results imply that the B*2705- and B*2709-bound peptide repertoires are largely overlapping. Thus, to the extent to which linkage of HLA-B27 with AS is related to the peptide-presenting properties of this molecule, our results would imply that peptides within a relatively small fraction of the HLA-B27-bound peptide repertoire influence susceptibility to this disease.     

Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes

As part of an ongoing study of early human immunodeficiency virus type 1 (HIV-1) infection in sub-Saharan African countries, we have identified 134 seroconverters (SCs) with distinct acute-phase (peak) and early chronic-phase (set-point) viremias. SCs with class I human leukocyte antigen (HLA) variants B*44 and B*57 had much lower peak viral loads (VLs) than SCs without these variants (adjusted linear regression beta values of -1.08 ± 0.26 log(10) [mean ± standard error] and -0.83 ± 0.27 log(10), respectively; P < 0.005 for both), after accounting for several nongenetic factors, including gender, age at estimated date of infection, duration of infection, and country of origin. These findings were confirmed by alternative models in which major viral subtypes (A1, C, and others) in the same SCs replaced country of origin as a covariate (P ≤ 0.03). Both B*44 and B*57 were also highly favorable (P ≤ 0.03) in analyses of set-point VLs. Moreover, B*44 was associated with relatively high CD4(+) T-cell counts during early chronic infection (P = 0.02). Thus, at least two common HLA-B variants showed strong influences on acute-phase as well as early chronic-phase VL, regardless of the infecting viral subtype. If confirmed, the identification of B*44 as another favorable marker in primary HIV-1 infection should help dissect mechanisms of early immune protection against HIV-1 infection.     

The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions

HLA-B*2704 is strongly associated with ankylosing spondylitis. B*2706, which differs from B*2704 by two amino acid changes, is not associated with this disease. A systematic comparison of the B*2704- and B*2706-bound peptide repertoires was carried out to elucidate their overlap and differential features and to correlate them with disease susceptibility. Both subtypes shared about 90% of their peptide repertoires, consisting of peptides with Arg(2) and C-terminal aliphatic or Phe residues. B*2706 polymorphism influenced specificity at three anchor positions: it favored basic residues at P3 and POmega-2 and impaired binding of Tyr and Arg at POmega. Thus, the main structural feature of peptides differentially bound to B*2704 was the presence of C-terminal Tyr or Arg, together with a strong preference for aliphatic/aromatic P3 residues. This is the only known feature of B*2704 and B*2706 that correlates to their differential association with spondyloarthropathy. The concomitant presence of basic P3 and POmega-2 residues was observed only among peptides differentially bound to B*2706, suggesting that it impairs binding to B*2704. Similarity between peptide overlap and the degree of cross-reaction with alloreactive T lymphocytes suggested that the majority of shared ligands maintain unaltered antigenic features in the context of both subtypes.     

A new HLA-B44 subtype,B*4406, differing in exon 2

The name B ^*4406 was officially assigned by the WHO Nomenclature Committee in February 1995. This follows the agreed policy that, subject to the conditions stated in the most recent Nomenclature Report (Bodmer et al. 1994), names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report. The nucleotide sequences reported in this Papers have been submitted to the EMBL nucleotide sequence database and have been assigned the accession numbers X83400 (HLA-B promoter region), X83401 (exon 1), X83402 (exon 2), and X83403 (exon 3)     

Developmental profiles of three embryo-lethal maize mutants lacking leaf primordia: ptd*-1130, cp*-1418, and bno*-747B

The defective kernel (dek) mutants of maize are altered in both their embryo and endosperm development. Earlier studies have indicated that some of the dek mutants are unable to form shoot apical meristems or leaf primoirda. We have examined three embryo lethal dek mutants of this type, ptd*-1130, cp*-1418, and bno*-747B, to obtain a developmental profile for each. Allelism tests show that these three mutants are not allelic. Embryos were examined in early, mid-, and late kernel development as well as at kernel maturity by dissection and sectioning procedures and also at kernel maturity by scanning electron microscopy. All three mutants lag behind normal embryos in their rate of development. Embryos of ptd*-1130 reached the transition stage by early kernel development and progressed no further but underwent cell enlargement and necrosis during late kernel development. Embryos of cp*-1418 reached an early coleoptilar stage by midkernel development. They subsequently increased in size but did not form any leaf primordia. At kernel maturity, they no longer had a shoot apical meristem but often had a well formed root meristem. They appeared to remain healthy and did not become necrotic. Embryos of bno*747B reached the early coleoptilar stage by early kernel development but progressed no further. By kernel maturity, they had grown into masses of irregularly shaped embryonic tissue that no longer resembled any normal embryo stage but were not necrotic. None of these three mutants responded to attempts to support continued embryo development when cultured, but all three mutants formed callus on N6 and MS media supplemented with 2,4-D. These results indicate that these mutants are all uniformly blocked at specific stages early in embryonic development, have different subsequent developmental fates, and represent three different genes performing unique functions that are essential for embryogenesis.     

长效与常规IFN-alpha治疗慢性病毒性肝炎的临床疗效

目的：探讨长效与常规alpha- 干扰素（Interferon alpha, IFN alpha）治疗慢性病毒性乙型肝炎（Chr- onic viral hepatitis B, CVHB）的临床疗 效。方法：回顾性分析2010 年1 月~2012 年1 月我院收治的97 例CVHB 患者，在常规黄芩苷治疗方案的基础上，对照组采用常 规IFN alpha-1b 治疗，观察组采用长效IFN alpha-2a 治疗。观察并比较两组患者治疗前后肝功能及不良反应情况。结果：经过48 周治疗， 两组CVHB患者肝功能较治疗前均有显著改善；观察组患者ALT、AST、HA、LN 及r球蛋白（r-G）均显著低于对照组，差异有统 计学意义（P<0.05）；治疗48 周后，观察组患者HBeAg、HBsAg 及HBV-DNA 转阴率显著高于对照组，差异有统计学意义（P<0. 05）；在治疗期间，观察组腹胀及恶心、纳差、乏力等不良反应发生率显著低于对照组，差异有统计学意义（P<0.05）。结论：长效IFN alpha-2a 治疗CVHB 较常规IFN alpha-1b 疗法更有效改善患者肝功能、提高乙型肝炎病毒转阴率，不良反应少，值得推广。     

睾丸特异抗原C_2B细胞抗原决定簇的定位

免疫性不育病人的血清（ＩＰＳ）能１００％地抑制人体外受精．用该血清筛选人睾丸ｃＤＮＡ基因表达文库,发现了一种新的睾丸特异抗原（称作Ｃ２）．通过ＤＮＡ顺序研究,并与基因库中的有关同源性基因数据进行比较,证实Ｃ２是一个新的特异蛋白．Ｃ２基因仅与睾丸组织的ｍＲＮＡ杂交．该克隆在大肠杆菌中所表达的融合蛋白能够被３个不同的不育病人血清识别．利用嵌套缺失和Ｗｅｓｔｅｒｎ印迹的方法研究其抗原决定簇定位,发现Ｂ细胞抗原决定簇在羧基端２９个氨基酸范围内．用ＧＣＧ软件分析该抗原的氨基酸的亲水性和疏水性以及其存在于蛋白表面的可能性,确定其中的１５个氨基酸为抗原决定簇所必需,并合成了多肽     

Identification of UGT2B9*2 and UGT2B33 isolated from female rhesus monkey liver

Two UDP-glucuronosyltransferases (UGT2B9(*)2 and UGT2B33) have been isolated from female rhesus monkey liver. Microsomal preparations of the cell lines expressing the UGTs catalyzed the glucuronidation of the general substrate 7-hydroxy-4-(trifluoromethyl)coumarin in addition to selected estrogens (beta-estradiol and estriol) and opioids (morphine, naloxone, and naltrexone). UGT2B9(*)2 displayed highest efficiency for beta-estradiol-17-glucuronide production and did not catalyze the glucuronidation of naltrexone. UGT2B33 displayed highest efficiency for estriol and did not catalyze the glucuronidation of beta-estradiol. UGT2B9(*)2 was found also to catalyze the glucuronidation of 4-hydroxyestrone, 16-epiestriol, and hyodeoxycholic acid, while UGT2B33 was capable of conjugating 4-hydroxyestrone, androsterone, diclofenac, and hyodeoxycholic acid. Three glucocorticoids (cortisone, cortisol, and corticosterone) were not substrates for glucuronidation by liver or kidney microsomes or any expressed UGTs. Our current data suggest the use of beta-estradiol-3-glucuronidation, beta-estradiol-17-glucuronidation, and estriol-17-glucuronidation to assay UGT1A01, UGT2B9(*)2, and UGT2B33 activity in rhesus liver microsomes, respectively.     

Modification of Protein Synthesis by Vitamin B12 in the Marine Algal Flagellate Neochloris pseudoalveolaris*

SYNOPSIS. A strain of the marine algal flagellate Neochloris pseudoalgeolaris required only an inorganic medium for growth; however, in media containing vitamin B₁₂ it became greener, protein synthesis was modified, and the levels of DNA and RNA increased. By isotope tracer technics, transmethylation of the methyl group of methionine was found to play a role in modulation of protein synthesis governed by the vitamin. These results indicate that vitamin B₁₂ stimulates synthesis of chloroplasts in this algal strain.